Clinical Trials Browser

Withdrawn × Carcinoma, Transitional Cell × Nivolumab × Clear all

NCT05496192 2023-04-14

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Phase 2 Withdrawn

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma